Viridian Therapeutics

Yahoo Finance • 2 days ago

Viridian Therapeutics price target lowered to $36 from $40 at Truist

Truist lowered the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $40 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts ac... Full story

Yahoo Finance • 3 days ago

Viridian Metals Secures $225,000 Maximum JEA Funding; Adopts Quarterly Reporting Exemption

OTTAWA, April 08, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) reports that it has been awarded $225,000 under the Junior Exploration Assistance (“JEA”) program, representing the maximum funding... Full story

Yahoo Finance • 4 days ago

Stifel sees path towards differentiation for Viridian after Amgen data

Stifel analyst Alex Thompson notes that Amgen (AMGN) announced positive topline results for the Phase 3 on-body infusion study of Tepezza achieving a 77% rate of proptosis response, which comes in higher on both an absolute and placebo-adj... Full story

Yahoo Finance • 11 days ago

Morning Movers: Sysco dips following deal to acquire Jetro Restaurant Depot

Stock futures are modestly higher to start the week, indicating a potential rebound at the open following five consecutive weeks of declines across major indexes. Markets are stabilizing slightly after last week’s sustained selloff, but th... Full story

Yahoo Finance • 12 days ago

Stocks Pressured by Economic Fallout from Iran War

The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.39%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.11%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.78%.  June E-mini S&P futures (ESM26) fell -0.43%, and June... Full story

Yahoo Finance • 12 days ago

Stocks to watch on Monday after market: VRDN, BSX, MTB, AL

[manhattan office building] franckreporter/iStock via Getty Images Wall Street’s major market averages closed mostly lower on Monday as investors looked to navigate the holiday-shortened trading week with eyes continuing to focus on the M... Full story

Yahoo Finance • 12 days ago

Stocks Supported by Lower Bond Yields

The S&P 500 Index ($SPX) (SPY) today is up +0.58%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.91%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.30%.  June E-mini S&P futures (ESM26) are up +0.38%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 12 days ago

Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results

Viridian Therapeutics stock crashed Monday on "positive, but lackluster" final-phase results for its thyroid eye disease treatment. Continue Reading... Full story

Yahoo Finance • 12 days ago

Stocks Rebound as T-note Yields Tumble

The S&P 500 Index ($SPX) (SPY) today is up +0.42%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.32%.  June E-mini S&P futures (ESM26) are up +0.40%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 21 days ago

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,... Full story

Yahoo Finance • 23 days ago

Bambusa Therapeutics Appoints Todd James Chief Financial Officer

- Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at Acceleron Pharma prior to its $11.5... Full story

Yahoo Finance • 23 days ago

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools

Key Points VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both tradi... Full story

Yahoo Finance • 24 days ago

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position... Full story

Yahoo Finance • 24 days ago

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down

On February 17, 2026, VR Adviser, LLC disclosed in a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix(NASDAQ:OCUL), an estimated $71.01 million trade based on quarterly average pricing. VR... Full story

Yahoo Finance • 27 days ago

VR Adviser Adds Over 1 Million Savara Shares

According to a filing with the Securities and Exchange Commission dated Feb. 17, VR Adviser, LLC increased its position in Savara(NASDAQ:SVRA) by 1,059,332 shares during the fourth quarter. The fund’s Savara stake ended the quarter valued... Full story

Yahoo Finance • last month

RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 10 Fastest Growing NASDAQ Stocks to Buy.RBC Capital Lowers its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating On February 27, 2026, RBC C... Full story

Yahoo Finance • 4 months ago

Huge Insider Buying in MGM and Salesforce

JasonDoiy / Getty Images As the year begins to wind down, investors are looking to position themselves for 2026. In recent days, insiders, including beneficial owners, at Crescent Biopharma Inc. (NASDAQ: CBIO), MGM Resorts International (... Full story

Yahoo Finance • 4 months ago

Viridian Metals Announces Closing of First Tranche of Financing and Short Form Vertical Amalgamation

Not for distribution to U.S. news wire services or for dissemination in the United States VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is pleased to announ... Full story

Yahoo Finance • 6 months ago

Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)

* Viridian Therapeutics (NASDAQ:VRDN [https://seekingalpha.com/symbol/VRDN]) announced that its compensation committee has approved the grant of non-qualified stock options to purchase 147,650 shares of its common stock to four new emplo... Full story

Yahoo Finance • 8 months ago

Viridian licenses thyroid eye disease treatments to Kissei in Japan

WALTHAM, Mass. - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a clinical-stage biotechnology company with a market capitalization of $1.37 billion, has entered into an exclusive licensing agreement with Kissei Pharmaceutical Co., Ltd. for th... Full story